Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies

被引：0
|
作者：
Stefanie Förderreuther
Qi Zhang
Virginia L. Stauffer
Sheena K. Aurora
Miguel J. A. Láinez
机构：
[1] Ludwig Maximilian University,Department of Neurology
[2] Sanofi,undefined
[3] Eli Lilly and Company,undefined
[4] Lilly Corporate Center,undefined
[5] Hospital Clínico Universitario,undefined
[6] Universidad Católica de Valencia,undefined
来源：
The Journal of Headache and Pain | 2018年 / 19卷
关键词：
Galcanezumab; Migraine; Preventive; Persistence; Maintenance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Efficacy of galcanezumab for migraine prevention in patients with a medical history of anxiety and/or depression: a post hoc analysis of the phase 3, randomized, double-blind, placebo-controlled REGAIN, and pooled EVOLVE-1 and EVOLVE-2 studies (vol 60, pg 2202, 2020)
    Smitherman, T. A.
    HEADACHE, 2022, 62 (01): : 114 - 116
  • [22] Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)
    Silberstein, Stephen D.
    Stauffer, Virginia L.
    Day, Katie A.
    Lipsius, Sarah
    Wilson, Maria-Carmen
    JOURNAL OF HEADACHE AND PAIN, 2019, 20 (1):
  • [23] Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)
    Stephen D. Silberstein
    Virginia L. Stauffer
    Katie A. Day
    Sarah Lipsius
    Maria-Carmen Wilson
    The Journal of Headache and Pain, 2019, 20
  • [24] Efficacy of Galcanezumab in Patients Who Failed to Respond to Preventives Previously: Results from EVOLVE-1, EVOLVE-2 and REGAIN Studies
    Zhang, Q.
    Ruff, D.
    Pearlman, E.
    Govindan, S.
    Aurora, S.
    HEADACHE, 2018, 58 : 165 - 166
  • [25] Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)
    Stephen D. Silberstein
    Virginia L. Stauffer
    Katie A. Day
    Sarah Lipsius
    Maria-Carmen Wilson
    The Journal of Headache and Pain, 2019, 20
  • [26] Galcanezumab in chronic migraine The randomized, double-blind, placebo-controlled REGAIN study
    Detke, Holland C.
    Goadsby, Peter J.
    Wang, Shufang
    Friedman, Deborah I.
    Selzler, Katherine J.
    Aurora, Sheena K.
    NEUROLOGY, 2018, 91 (24) : E2211 - E2221
  • [27] EFFICACY OF GALCANEZUMAB IN PATIENTS WHO FAILED TO RESPOND TO PREVENTIVES PREVIOUSLY: RESULTS FROM EVOLVE-1, EVOLVE-2 AND REGAIN STUDIES
    Zhang, Q.
    Ruff, D. D.
    Pearlman, E. M.
    Govindan, S.
    Aurora, S.
    CEPHALALGIA, 2018, 38 : 51 - 52
  • [28] Efficacy of galcanezumab in patients who failed to respond to preventives previously: results from EVOLVE-1, EVOLVE-2 and REGAIN studies
    Zhang, Q.
    Ruff, D. D.
    Pearlman, E. M.
    Govindan, S.
    Aurora, S. K.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 298 - 298
  • [29] Phase 3 Studies (EVOLVE-1 & EVOLVE-2) of Galcanezumab in Episodic Migraine: Subgroup Analyses of Efficacy by Low-Versus High-Frequency of Migraine Headaches
    Silberstein, Stephen
    Stauffer, Virginia L.
    Day, Kathleen A.
    Lipsius, Sarah
    Wilson, Maria-Carmen
    NEUROLOGY, 2019, 92 (15)
  • [30] Phase 3 studies (EVOLVE-1 & EVOLVE-2) of galcanezumab in episodic migraine: subgroup analyses of efficacy by low-versus high-frequency of migraine headaches
    Silberstein, Stephen
    Stauffer, Virginia L.
    Day, Katie
    Zhang, Qi
    Lipsius, Sarah
    Wilson, Maria-Carmen
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
12345